ClinicalTrialsFinder
RecruitingNCT06440018

INSPIRE: a Multi-Cancer Early Detection Study

INSPIRE: Integrating Circulating DNA Methylation and Fragmentomics to Scan and Pinpoint Cancer Signals Effectively

Sponsor

Singlera Genomics Inc.

Enrollment

5,350 participants

Start Date

Jul 20, 2024

Study Type

OBSERVATIONAL

Conditions

Breast CancerLiver CancerColorectal, CancerEsophageal CancerPancreatic CancerGastric CancerOvarian CancerCervical CancerEndometrial CancerProstate CancerCholangiocarcinomaLung CancerBladder Cancer

Summary

This research constitutes a multi-centric, case-control designed investigation aimed at developing and implementing a blinded validation of a machine learning-powered, multi-cancer early detection model. This is to be achieved through the prospective collection of blood specimens from newly diagnosed cancer patients and individuals devoid of a confirmed cancer diagnosis

Eligibility

Min Age: 40 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is developing a blood test that can detect multiple types of cancer at an early stage — before symptoms appear — by analyzing fragments of tumor DNA circulating in the bloodstream. Participants include both people newly diagnosed with cancer and healthy adults. **You may be eligible if...** - You are between 40 and 75 years old - You have been newly diagnosed with cancer (of any type) and have not yet started any treatment - OR you are a healthy adult with no cancer diagnosis **You may NOT be eligible if...** - You have already started cancer treatment (surgery, radiation, chemotherapy, immunotherapy, etc.) - You have previously had cancer - You are currently enrolled in another cancer clinical trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Fudan University

Shanghai, Shnaghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06440018

Related Trials

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

NCT034128771 location

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT0422154257 locations

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

NCT03151629121 locations

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT0702362782 locations

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

NCT0356434052 locations